Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients

• DOI: 10.18632/oncotarget.24148
• Publication Date: 2018-01-11T06:33:52Z
• Authors: Karolina Tecza; Jolanta Pamula-Pilat; Joanna Lanuszewska; Dorota Butkiewicz; Ewa Grzybowska
• Keywords: DPYD; ERCC1; GSTP1; XRCC1

// Karolina Tecza 1 , Jolanta Pamula-Pilat Joanna Lanuszewska Dorota Butkiewicz and Ewa Grzybowska Center for Translational Research Molecular Biology of Cancer, Maria Sklodowska-Curie Memorial Cancer Institute Oncology, Gliwice, Poland Correspondence to: Grzybowska, email: [e-mail] Keywords: breast cancer; FAC; chemotherapy; polymorphism; treatment toxicity Received: October 06, 2017 Accepted: January 02, 2018 Published: 10, ABSTRACT The differences in patients' response to the same medication, included, are one major problems cancer treatment. Chemotherapy makes a significant clinical problem due decreased quality life, prolongation reinforcement negative emotions associated with therapy. In this study we evaluated genetic risk factors FAC chemotherapy-related toxicities group 324 patients. Selected genes their polymorphisms were involved drugs transport ( ABCB1, ABCC2, ABCG2,SLC22A16 ), metabolism ALDH3A1, CBR1, CYP1B1, CYP2C19, DPYD, GSTM1, GSTP1, GSTT1, MTHFR,TYMS DNA damage recognition, repair cell cycle control ATM, ERCC1, ERCC2, TP53, XRCC1 ). multifactorial models that combine modifiers characteristics constructed 12 toxic symptoms. majority was dependent on modifications components more than pathway drugs, while impact level comparable ones. For carriers multiple high chance developing given symptom significantly elevated which proved factor-dosage effect. We found strongest associations between concurrent presence - overall recurrent anemia, nephrotoxicity early nausea responsible repair, pathways. These results indicate possibility selection patients expected tolerance consequently chemotherapy completion without dose reduction, delays decline life.